All In Biotech

Drug Trial Radar · NCT00103610

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Comparative Trial of AMD3100 Plus G-CSF Versus G-CSF Plus Placebo to Mobilize and Collect ≥ 5 * 10^6 CD34+ Cells/kg in Non-Hodgkin's Lymphoma Patients for Autologous Transplantation

Last checked: Nov 20, 2026Latest source record: Mar 13, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 298 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

298

Actual

Start

Jan 2005

Primary completion

Jul 2006

Study completion Dec 2007

Sponsor

Lead sponsor
Genzyme, a Sanofi CompanySanofi (SNY)
Sponsor type
Industry
First posted
Feb 14, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 78 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF or generic name filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in non-Hodgkin's lymphoma patients for autologous transplantation.

Conditions

  • Lymphoma, Non-Hodgkin

Interventions

  • Granulocyte colony-stimulating factor plus plerixaforDrug

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

  • Granulocyte colony-stimulating factor plus placeboDrug

    Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5\*10\^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of Participants Able to Achieve Target (≥ 5*10^6 CD34+ Cells/kg) in 4 or Fewer Days of ApheresisTime frame: Days 5 to 8

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • City of Hope Samaritan Bone Marrow Transplant Program

    Phoenix, Arizona

  • City of Hope National Medical Center

    Duarte, California

  • Rocky Mountain Cancer Center

    Denver, Colorado

  • Yale University School of Medicine

    New Haven, Connecticut

  • Shands Teaching Hospital, University of Florida

    Gainesville, Florida

  • H. Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida

  • Loyola University Medical Center

    Maywood, Illinois

  • Indiana Blood and Marrow Transplantation Center

    Beech Grove, Indiana

  • University of Iowa Hospitals and Clinics

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Minnesota

    Minneapolis, Minnesota

  • Mayo Clinic

    Rochester, Minnesota

  • Kansas City Cancer Center

    Kansas City, Missouri

  • Washington University School of Medicine

    St Louis, Missouri

  • Nebraska Medical Center: Clarkson and University Hospitals

    Omaha, Nebraska

  • Roswell Park Cancer Institute

    Buffalo, New York

  • University of Rochester Medical Center

    Rochester, New York

  • Duke University Medical Center

    Durham, North Carolina

  • Case Western Reserve University

    Cleveland, Ohio

  • Cleveland Clinic Foundation

    Cleveland, Ohio

  • Oregon Health & Science University

    Portland, Oregon

  • Hospital of the University of Pennsylvania

    Philadelphia, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Wilford Hall Medical Center

    Lackland Air Force Base, Texas

  • Texas Transplant Institute

    San Antonio, Texas

  • University of Texas Health Science Center

    San Antonio, Texas

  • Virginia Commonwealth University

    Richmond, Virginia

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Vancouver General Hospital

    Vancouver, British Columbia, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.